Reports on the controversy surrounding the announcement made by Great Britain-based British Biotech PLC. concerning the settlement of a case with the U.S. Securities and Exchange Commission (SEC) regarding its cancer drug, marimastat. Allegations of the SEC concerning the behavior of the company towards its former head of research Andrew Miller; Reference to 1998 issue of t he journal Nature Biotechnology' vol. 16.